医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Amneal Announces New Biosciences Unit with Charles Lucarelli as President

2015年08月25日 PM11:24
このエントリーをはてなブックマークに追加


 

BRIDGEWATER, N.J.

Amneal today announced the creation of Amneal Biosciences, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC (www.amneal.com). Amneal Biosciences will focus exclusively on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics and biosimilars to healthcare providers globally.

“Having a dedicated company focused on the unique needs and logistics of this market segment allows Amneal to guarantee the same level of quality and service to healthcare institutions and professionals that we deliver to our existing retail customers,” explains Amneal co-CEO and Chairman Chirag Patel. “Amneal has a robust pipeline of both small-molecule injectable generics as well as biosimilars, and we expect to bring the first of these to market in early 2016. Our experienced Amneal Biosciences team provides the high degree of expertise these specialty products require.”

Heading Amneal Biosciences as President is pharmacy veteran Charles Lucarelli, MS, RPh. Charles joined Amneal in March of this year after a 37-year career at Memorial Sloan Kettering Cancer Center, including 25 years as Director of Pharmacy. In this position, Mr. Lucarelli took direct responsibility for the pharmacy department and its regional sites and was accountable for inpatient/outpatient pharmaceutical services, clinical services, and hospital-wide investigational drug and research services. Charles was a co-investigator on numerous drug studies at Memorial Sloan Kettering. He has authored numerous articles in addition to the book “Herb Drug Interactions in Oncology” and is an internationally known speaker.

“It is an honor to serve as President of Amneal Biosciences and lead this talented group of professionals at such a pivotal time in our company’s evolution,” said Mr. Lucarelli. “Our robust product pipeline will bring the Amneal legacy of quality and customer service to a segment in need of therapeutic affordability and reliable supply.”

About Amneal Pharmaceuticals

Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods. Since its inception in 2002, Amneal has invested extensively in R&D resources, manufacturing infrastructure, and strategic expansion opportunities—all contributing to its significant growth. The Company prides itself on its unwavering commitment to quality, strong business relationships, and innovative approach to maximizing value. Amneal is privately-held with U.S. headquarters in Bridgewater, New Jersey and international headquarters in Zug, Switzerland. For more information, please visit www.amneal.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150825005928/en/

CONTACT

Amneal Pharmaceuticals LLC
Apurva Saraf
Vice President, Global
Strategy & Corporate Development
Dir: +1 (908) 947.3740
M:
+1 (631) 742.7674
apurvas@amneal.com
or
Jim
Luce
Executive Vice President, Sales & Marketing
M: +1
(949) 500.5756
jim@amneal.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent